ibrutinib and venetoclax upfront for high-risk cll
Published 4 years ago • 153 plays • Length 1:38Download video MP4
Download video MP3
Similar videos
-
2:00
obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials
-
2:43
outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
-
5:52
understanding ultra high-risk cll and advances with ibrutinib therapy
-
1:28
ibrutinib and venetoclax: a powerful combination in frontline and relapsed cll
-
1:56
ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
-
2:57
selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in cll
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
7:29
venetoclax obinutuzumab: impact on cll management
-
2:18
first-line ibrutinib and venetoclax in cll
-
1:03
maic of zanubrutinib and venetoclax ibrutinib in treatment-naïve cll
-
1:59
acalabrutinib, venetoclax and obinutuzumab upfront for cll
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
2:21
captivate: ibrutinib and venetoclax in cll
-
5:54
updates from captivate: ibrutinib and venetoclax for cll
-
4:21
hovon 141/vision trial update: mrd-guided venetoclax ibrutinib treatment for r/r cll
-
3:02
combined ibrutinib and venetoclax in patients with treatment-naïve high-risk cll
-
1:47
ash cll highlights: ibrutinib-venetoclax combination & undetectable mrd in ighv-mutated patients
-
2:45
optimizing the combination of ibrutinib plus venetoclax in cll
-
1:05
final analysis of the alpine trial: zanubrutinib vs ibrutinib in r/r cll
-
1:21
ibrutinib, rituximab and venetoclax in the treatment of patients with newly diagnosed mcl
-
6:34
3-year follow-up of obinutuzumab, ibrutinib and venetoclax for cll
-
1:23
interim analysis of the flair study: efficacy of ibrutinib plus venetoclax in ighv unmutated cll